Trial
NCT01559129
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Celgene
Collaborators
—
Condition
Scleroderma, Systemic
Intervention
Pomalidomide (CC-4047)
Why stopped
Enrollment was stopped early (see limitations and caveats section).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-01